A61P 9/02
Non-specific cardiovascular stimulants
Official title: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
A61P9/02 (Non-specific cardiovascular stimulants) appears on 1,614 US grants and 1,992 published applications in this corpus.
Search patents in A61P- Granted patents
- 1,614
- Published applications
- 1,992
- Assignees
- 850
- Inventors
- 4,686
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 1 | 0 |
| 1980 | 2 | 0 |
| 1981 | 1 | 0 |
| 1982 | 2 | 0 |
| 1983 | 6 | 0 |
| 1984 | 3 | 0 |
| 1985 | 9 | 0 |
| 1986 | 4 | 0 |
| 1987 | 6 | 0 |
| 1988 | 7 | 0 |
| 1989 | 3 | 0 |
| 1990 | 7 | 0 |
| 1991 | 10 | 0 |
| 1992 | 9 | 0 |
| 1993 | 7 | 0 |
| 1994 | 11 | 0 |
| 1995 | 14 | 0 |
| 1996 | 10 | 0 |
| 1997 | 32 | 0 |
| 1998 | 27 | 0 |
| 1999 | 42 | 0 |
| 2000 | 38 | 0 |
| 2001 | 59 | 16 |
| 2002 | 81 | 94 |
| 2003 | 69 | 128 |
| 2004 | 46 | 141 |
| 2005 | 50 | 117 |
| 2006 | 64 | 110 |
| 2007 | 68 | 111 |
| 2008 | 74 | 121 |
| 2009 | 67 | 144 |
| 2010 | 82 | 166 |
| 2011 | 85 | 85 |
| 2012 | 72 | 91 |
| 2013 | 79 | 77 |
| 2014 | 75 | 74 |
| 2015 | 54 | 83 |
| 2016 | 45 | 54 |
| 2017 | 62 | 49 |
| 2018 | 35 | 61 |
| 2019 | 42 | 48 |
| 2020 | 32 | 46 |
| 2021 | 29 | 41 |
| 2022 | 26 | 43 |
| 2023 | 20 | 36 |
| 2024 | 14 | 19 |
| 2025 | 19 | 20 |
| 2026 | 9 | 17 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Superoxide dismutase-loaded porous polymersomes as highly efficient antioxidant nanoparticles11 Aug 2026US 12,702,699 B2The Trustees of the University of Pennsylvania
- Treatment of viral infections, of organ injury, and of related conditions using a HIF prolyl hydroxylase inhibitor or a HIF-alpha stabilizer19 May 2026US 12,629,357 B2Akebia Therapeutics, Inc.
- Antagonist anti-NPR1 antibodies and methods of use thereof21 Apr 2026US 12,606,618 B2Regeneron Pharmaceuticals, Inc.
- Systems and methods for treating an opioid-induced adverse pharmacodynamic response24 Mar 2026US 12,582,647 B2Purdue Pharma L. P.
- Methods and treatment of trauma24 Mar 2026US 12,582,674 B2Hemanext Inc.
- Compositions and methods for treatment of septic shock8 Oct 2026US 2026/0306579 A1Peroxitech Therapeutics, Inc.
- Norepinephrine compositions and methods therefor17 Sep 2026US 2026/0272855 A1Nevakar Injectables Inc.
- Norepinephrine compositions and methods therefor10 Sep 2026US 2026/0263388 A1Nevakar Injectables Inc.
- Norepinephrine compositions and methods therefor10 Sep 2026US 2026/0263389 A1Nevakar Injectables Inc.
- Norepinephrine compositions and methods therefor10 Sep 2026US 2026/0263390 A1Nevakar Injectables Inc.
Most cited
By later US patents
- Pharmaceutical compositions containing an omega-3 fatty acid oil306US 6,284,268 B1Cyclosporine Therapeutics Limited · 2001
- Albumin fusion proteins comprising GLP-1 polypeptides198US 7,141,547 B2Human Genome Sciences, Inc. · 2006
- Methods for using tetanus toxin for beneficial purposes in animals (mammals)171US 7,494,661 B22009
- Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders138US 6,004,925 A1999
- Sirtuin modulating compounds126US 7,345,178 B2Sirtris Pharmaceuticals, Inc. · 2008